| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
InMode (NASDAQ:INMD) affirms FY2025 sales outlook from $365.000 million-$375.000 million to $365.000 million-$375.000 million v...
InMode (NASDAQ:INMD) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.35 by 7.34 ...
https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safe...
Canaccord Genuity analyst Caitlin Cronin maintains InMode (NASDAQ:INMD) with a Hold and raises the price target from $14 to ...
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) from Hold to Hold.
Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026Maintains Board Has Le...